Abstract
Genotoxic therapy-induced persistent damage to non-hematopoietic tissues promotes myeloid leukemia development by conferring advantage to p53-deficient preleukemic clones and driving acquisition of additional lesions in DNA damage response genes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have